Evgen Pharma poised for a pivotal year
19th June 2018
2018 is a key year in the development of Evgen Pharma Plc (LON:EVG), the Cheshire-based business which has made rapid progress since joining AIM. It now has two Phase II
2018 is a key year in the development of Evgen Pharma Plc (LON:EVG), the Cheshire-based business which has made rapid progress since joining AIM. It now has two Phase II
Evgen Pharma’s Dr Stephen Franklin caught up with DirectorsTalk for an exclusive interview to discuss the interim update on their STEM clinical trial in this exclusive interview with DirectorsTalk
Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about its Interim update on STEM trial. Stephen reminds us what the STEM trial is, its objectives, why its
Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Evgen Pharma plc (LON:EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, has announced its final results for the year ended 31 March
Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has announced an encouraging interim update on STEM (SFX-01 in the
Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March
Evgen Pharma PLC (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has today announced that Dr Stephen Franklin, the Company’s CEO, will
Steve Franklin, CEO of Evgen Pharma, said: “We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants
Evgen Pharma PLC (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has today announced that Steve Franklin, the Company’s CEO, will present
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
